His primary scientific interests are in Internal medicine, Endocrinology, Diabetes mellitus, Diabetic nephropathy and Angiotensin II. His research is interdisciplinary, bridging the disciplines of Cardiology and Internal medicine. As part of the same scientific family, he usually focuses on Endocrinology, concentrating on Vascular endothelial growth factor A and intersecting with Cytokine.
His research integrates issues of Heart failure, Pathogenesis, Randomized controlled trial, Disease and Physical therapy in his study of Diabetes mellitus. His work carried out in the field of Diabetic nephropathy brings together such families of science as Thioredoxin, TXNIP, Nitric oxide synthase and Nephropathy. His Angiotensin II research integrates issues from Irbesartan, Colocalization and Intercalated Cell.
His main research concerns Internal medicine, Endocrinology, Diabetes mellitus, Diabetic nephropathy and Kidney. His Internal medicine research is multidisciplinary, incorporating elements of Nephropathy and Cardiology. His study focuses on the intersection of Endocrinology and fields such as Fibrosis with connections in the field of Tranilast.
His work deals with themes such as Disease, Blood pressure, Pathogenesis and Intensive care medicine, which intersect with Diabetes mellitus. His study in Diabetic nephropathy is interdisciplinary in nature, drawing from both Immunology, Protein kinase C, Ruboxistaurin, Podocyte and Transforming growth factor beta. His studies deal with areas such as Growth factor, Pharmacology and Pathology as well as Kidney.
Richard E. Gilbert spends much of his time researching Internal medicine, Diabetes mellitus, Cardiology, Endocrinology and Kidney disease. His Internal medicine research incorporates themes from Empagliflozin and Type 2 diabetes. His Diabetes mellitus study combines topics from a wide range of disciplines, such as Insulin, Disease and Myocardial infarction.
His Cardiology study combines topics in areas such as Blood pressure and Systole. Richard E. Gilbert works in the field of Endocrinology, focusing on Erythropoietin in particular. The various areas that he examines in his Kidney disease study include Nephron, Nephrology, Diabetic nephropathy and Intensive care medicine.
Richard E. Gilbert focuses on Internal medicine, Diabetes mellitus, Kidney disease, Empagliflozin and Endocrinology. The study incorporates disciplines such as Intensive care medicine, Canagliflozin and Cardiology in addition to Internal medicine. His Sodium glucose transporter 2 study in the realm of Diabetes mellitus connects with subjects such as Adrenergic beta-Antagonists.
His research in Kidney disease tackles topics such as Fibrosis which are related to areas like Disease and Cytokine. His study looks at the relationship between Empagliflozin and fields such as Coronary artery disease, as well as how they intersect with chemical problems. His research on Endocrinology frequently connects to adjacent areas such as Plerixafor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?
Richard E. Gilbert;Mark E. Cooper.
Kidney International (1999)
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.
Mark E. Cooper;Dimitria Vranes;Sherif Youssef;Steven A. Stacker.
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
Kaberi Dasgupta;Robert R. Quinn;Kelly B. Zarnke;Doreen M. Rabi.
Canadian Journal of Cardiology (2013)
Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
Kara A. Nerenberg;Kelly B. Zarnke;Alexander A. Leung;Kaberi Dasgupta.
Canadian Journal of Cardiology (2018)
Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations
Marc A. Pohl;Samuel Blumenthal;Daniel J. Cordonnier;Fernando De Alvaro.
Journal of The American Society of Nephrology (2005)
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy
Daniel G. Hackam;Nadia A. Khan;Brenda R. Hemmelgarn;Simon W. Rabkin.
Canadian Journal of Cardiology (2010)
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Richard E Gilbert;Allison J Cox;L L Wu;Terri J Allen.
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension
Alexander A. Leung;Kara Nerenberg;Stella S. Daskalopoulou;Kerry McBrien.
Canadian Journal of Cardiology (2016)
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Alexander A. Leung;Stella S. Daskalopoulou;Kaberi Dasgupta;Kerry McBrien.
Canadian Journal of Cardiology (2017)
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy
Nadia A. Khan;Brenda Hemmelgarn;Robert J. Herman;Chaim M. Bell.
Canadian Journal of Cardiology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: